Biocon Ltd
NSE: BIOCON BSE: 532523
₹373.75
(0.97)%
Tue, 03 Feb 2026, 08:43 am
Market Cap593.57B
PE Ratio94.13
Dividend0.14
Health Technology
Pharmaceuticals: Major
24.5Kbiocon ltd History
2002
- Kiran Mazumdar-Shaw is Chairman and Managing Director of Biocon India Group.
- Biocon appoints DSP Merrill Lynch and Kotak Mahindra for Rs 150-crore IPO.
- Biocon forms 50:50 JV Biocon-Shantha Biotech with Shantha Biotechnics for insulin markets.
2003
- ICICI Venture offloads 10% stake in Biocon.
2004
- Clinigene inaugurates human pharmacology unit.
- Biocon IPO of 10 million shares at Rs 315, lists at Rs 425.
- Biocon signs nine-year export contract with Bristol-Myers Squibb for recombinant insulin.
- Biocon enters lifestyle drugs market.
- Clinigene re-accredited by College of American Pathologists.
- Biocon’s CIMAB JV licenses cancer drugs to CancerVax.
- Biocon and Syngene enter research agreement with Novartis.
- Biocon unveils new bio insulin.
2005
- Biocon signs MoU with Karolinska Institute.
- Kiran Mazumdar-Shaw receives Corporate Leadership Award from American India Foundation.
- Biocon signs licensing agreement with Bentley Pharmaceuticals.
2006
- Biocon ties up with ICICI Prudential Life Insurance.
- Biocon concludes Phase-IV trials of Insugem.
2007
- Biocon signs MOU with Neopharma for JV in GCC countries.
- Syngene enters research partnership with Bristol-Myers Squibb.
2008
- Biocon issues 1:1 bonus shares.
2009
- Biocon and Amylin enter agreement for peptide therapeutic for diabetes.
- Biocon launches BASALOG basal insulin.
- Biocon partners with ISB for Biocon Cell for Innovation Management.
2010
- Biocon launches comprehensive care division for critical illnesses.
- Biocon signs agreement with Teleradiology Solutions for Clinigene.
2011
- Biocon announces preliminary data on oral insulin candidate.
- Biocon commences biopharmaceutical facility project in Bio-XCell, Malaysia.
- Biocon launches INSUPen insulin delivery device.
- Clinigene enters collaborative clinical research services.
- Biocon wins Biospectrum BioPharma Company of the Year award.
- Biocon wins Best Design and Information Award at Bangalore India Bio.
2012
- Biocon wins Excellence in Environmental Management Award.
- Biocon wins Best Exhibitor Award at Bangalore India Bio.
- Biocon wins Golden Peacock National Quality Award.
- Biocon Research Centre inaugurated by Nobel Laureate Prof Kurt Wüthrich.
- Biocon enters option agreement with Bristol-Myers Squibb for IN-105 oral insulin.
2013
- Biocon launches ALZUMAb for psoriasis in India.
- Biocon enhances partnership with Mylan for insulin products.
- Biocon partners with CytoSorbents for CytoSorb sepsis therapy.
- Biocon ranked No. 6 among Top 20 Global Biotech Employers by Science Magazine.
- Biocon wins Best Design and Innovation Exhibitor Award at Bangalore India Bio.
2014
- Biocon receives Sir J C Bose Memorial Award for ALZUMAb launch.
- Biocon Foundation wins Asia Best CSR Practices Award for Cervical Cancer Screening.
- Biocon wins Thomson Reuters India Innovation Awards.
- Biocon launches breast cancer drug.
- Biocon partners with Advaxis for cancer immunotherapy.
- Biocon launches program with KGI.
2015
- Biocon Foundation receives WHO award.
- Biocon receives approval for Insulin Glargine in Mexico via PiSA Farmaceutica.
- Syngene files DRHP for IPO.
- Biocon launches ‘Winning with Diabetes’ campaign.
- NeoBiocon partners with Novartis for Vildagliptin in UAE.
- Biocon launches Hepatitis-C drug in India.
- Biocon ranked only Asian company in Top 20 Global Biotech Employers.
- Biocon inaugurates devices facility and launches Basalog One.
2016
- Biocon Academy launches career program in Quality Control Microbiology with BITS Pilani.
- Biocon receives Karnataka govt approval for Rs 1,060 cr plant.
- Biocon launches Insulin Glargine in Japan.
2017
- US FDA accepts BLA for Mylan and Biocon’s biosimilar Trastuzumab.
- Biocon wins MYR 300 million insulin contract from MoH Malaysia.
- Biocon Foundation collaborates with Karnataka govt for Smart eLAJ Clinics.
- Kiran Mazumdar-Shaw receives AWSM Award for Excellence 2017.
- Biocon launches KRABEVA biosimilar Bevacizumab in India.
- Biocon Drug Product Facility receives EIR with VAI status.
2018
- Biocon receives positive CHMP opinion for Semglee.
- Biocon receives 6 US FDA observations for Malaysia facility.
- Biocon announces global collaboration with Sandoz on biosimilars.
- Mylan and Biocon receive approvals for Semglee from European Commission and TGA Australia.
- Biocon ranked 7th on Top Global Pharma & Biotech Employers List.
- Biocon wins Best Corporate University and Best Quality Improvement Awards from CLO TISS.
2019
- Biocon wins ‘Best Initiative in Employee Wellness’ at Employee Engagement Leadership Awards.
- Biocon Biologics acquires to expand R&D footprint.
- Biocon and Mylan launch Semglee Insulin Glargine biosimilar in Australia.
- Biocon facility completes US FDA pre-approval inspection.
- Biocon and Mylan launch Herceptin biosimilar in US.
2020
- Biocon API facility completes US FDA pre-approval and GMP inspection.
- Biocon and Mylan win Sanofi patent litigation for Insulin Glargine device in US.
- Biocon and Mylan launch Fulphila biosimilar Pegfilgrastim in Canada.
- Biocon Biologics and Voluntis collaborate on digital therapeutics for insulins.
- Biocon ranked among Top 5 global biotech employers.
- Biocon launches Tacrolimus capsules in US.
2021
- Biocon launches Everolimus tablets in US.
- Biocon enters out-licensing deal with Tabuk Pharmaceuticals.
- Biocon Biologics’ interchangeable biosimilar Insulin Glargine preferred on Express Scripts’ US formulary.
- Biocon enters Dow Jones Sustainability Emerging Markets Index.
- Biocon partners with Tabuk Pharmaceuticals for speciality generics in Middle East.
2022
- Biocon initiates clinical study of Itolizumab for Ulcerative Colitis in India.
- Biocon Biologics completes acquisition of Viatris’ Global Biosimilars Business.
- Biocon enters commercialization agreement with Zentiva in Europe.
- Biocon ranks No. 8 in ‘Global Top Employers’ List by Science Magazine.
- Biocon Foundation receives ‘Mahatma Award 2022 for Excellence in Social Good.
- Biocon Sdn. Bhd. enters Malaysia Book of Records as largest integrated insulin facility.
2023
- Biocon partners with Sandoz for Adalimumab BS distribution in Japan.
- Biocon recognized as Asia IP Elite 2023; IPR Team named Team of the Year.
- Biocon completes integration of Viatris’ Biosimilar Business in 31 European countries.
- Biocon signs commercialization agreement with Juno Pharmaceuticals in Canada.
- Biocon acquires manufacturing facility of Eywa Pharma Inc.
- Biocon Biologics takes over commercialization of biosimilars from Viatris in 70+ emerging markets.
2024
- Biocon ranked among Science Magazine’s Top 10 Global Employers.
- Biocon Foundation honored with ‘Doing Good for Bharat Awards 2024’ in Healthcare Category for ‘eLAJ Smart Clinics’.
- Biocon partners with Tabuk Pharmaceuticals to commercialize GLP-1 products in Middle East.
- Biocon Foundation and IISc organize OCTF Conference on AI in Oral Cancer.
- Biocon signs semi-exclusive distribution deal for generic Saxenda (Liraglutide) in Mexico.
2025
- Biocon Biologics wins 'Data Privacy Program of the Year' at BW Tech World’s Tech Excellence Awards.
- Biocon Biologics wins two awards at Asia Pacific Biopharma Excellence Awards (ABEA).
- Biocon honored with Champion of CSR Award at ESG Impact Summit 2024.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800